
Xin Tian

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8089029/publications.pdf

Version: 2024-02-01



Χινι Τιανι

#	Article	IF	CITATIONS
1	BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL. Blood Advances, 2022, 6, 1732-1740.	2.5	13
2	Haematopoietic stem cell transplant patients have a high initial failure rate to hepatitis B vaccination that can be overcome with subsequent vaccination series. British Journal of Haematology, 2022, 196, 1404-1407.	1.2	0
3	Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model. Journal of Clinical Oncology, 2021, 39, 576-585.	0.8	74
4	Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. Blood, 2021, 137, 185-189.	0.6	110
5	Association of Cumulative Systolic Blood Pressure With Long-Term Risk of Cardiovascular Disease and Healthy Longevity. Hypertension, 2021, 77, 347-356.	1.3	43
6	A phenotypic risk score for predicting mortality in sickle cell disease. British Journal of Haematology, 2021, 192, 932-941.	1.2	9
7	Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naÃ ⁻ ve chronic lymphocytic leukemia: a phase 2 study. Leukemia and Lymphoma, 2021, 62, 1816-1827.	0.6	0
8	Combined haploidentical and cord blood transplantation for refractory severe aplastic anaemia and hypoplastic myelodysplastic syndrome. British Journal of Haematology, 2021, 193, 951-960.	1.2	8
9	Clinical Outcomes in Patients with Multi-Hit <i>TP53</i> Chronic Lymphocytic Leukemia Treated with Ibrutinib. Clinical Cancer Research, 2021, 27, 4531-4538.	3.2	20
10	BASILICA Trial: One-Year Outcomes of Transcatheter Electrosurgical Leaflet Laceration to Prevent TAVR Coronary Obstruction. Circulation: Cardiovascular Interventions, 2021, 14, e010238.	1.4	34
11	Nonparametric estimation of risk tracking indices for longitudinal studies. Statistical Methods in Medical Research, 2020, 29, 481-497.	0.7	2
12	lbrutinib for Chronic Lymphocytic Leukemia with <i>TP53</i> Alterations. New England Journal of Medicine, 2020, 383, 498-500.	13.9	84
13	Time Course of LDL Cholesterol Exposure and Cardiovascular Disease Event Risk. Journal of the American College of Cardiology, 2020, 76, 1507-1516.	1.2	155
14	A phase <scp>II</scp> study of ibrutinib and short ourse fludarabine in previously untreated patients with chronic lymphocytic leukemia. American Journal of Hematology, 2020, 95, E310-E313.	2.0	3
15	Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors. Leukemia and Lymphoma, 2020, 61, 2375-2382.	0.6	16
16	Immune Response Following Quadrivalent Human Papillomavirus Vaccination in Women After Hematopoietic Allogeneic Stem Cell Transplant. JAMA Oncology, 2020, 6, 696.	3.4	18
17	A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen alloâ€immunized patients. British Journal of Haematology, 2020, 189, 551-558.	1.2	17
18	A prospective evaluation on the interaction of fluconazole and voriconazole on serum concentrations of budesonide in patients treated for gastrointestinal GVHD. Bone Marrow Transplantation, 2020, 55, 1085-1092.	1.3	2

XIN TIAN

#	Article	IF	CITATIONS
19	The BASILICA Trial. JACC: Cardiovascular Interventions, 2019, 12, 1240-1252.	1.1	183
20	Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL. Blood, 2019, 133, 2452-2455.	0.6	22
21	Ex Vivo Nicotinamide-Expanded (NAM-Expanded) Unrelated Cord Bloodtransplantation (UCB) for Refractory Severe Aplastic Anemia Results in Rapid Engraftment and Expedites Immune Recovery. Biology of Blood and Marrow Transplantation, 2019, 25, S210-S211.	2.0	3
22	Over-expression of PD-1 Does Not Predict Leukemic Relapse after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 216-222.	2.0	11
23	Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood, 2018, 131, 2357-2366.	0.6	166
24	Distinct Biomarker Profiles in Ex Vivo T Cell Depletion Graft Manipulation Strategies: CD34+ Selection versus CD3+/19+ Depletion in Matched Sibling Allogeneic Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 460-466.	2.0	3
25	Airway ciliary dysfunction: Association with adverse postoperative outcomes in nonheterotaxy congenital heart disease patients. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 755-763.e7.	0.4	17
26	Airway ciliary dysfunction and respiratory symptoms in patients with transposition of the great arteries. PLoS ONE, 2018, 13, e0191605.	1.1	17
27	Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood, 2017, 129, 1469-1479.	0.6	276
28	Statistical Indices for Risk Tracking in Longitudinal Studies. ICSA Book Series in Statistics, 2017, , 293-311.	0.0	1
29	Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib. JAMA Oncology, 2016, 2, 1656.	3.4	75
30	Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Blood, 2016, 128, 1940-1943.	0.6	149
31	Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica, 2015, 100, 1571-1578.	1.7	137
32	Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood, 2015, 126, 2213-2219.	0.6	198
33	lbrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncology, The, 2015, 16, 169-176.	5.1	344
34	Establishing normative nasal nitric oxide values in infants. Respiratory Medicine, 2015, 109, 1126-1130.	1.3	22
35	A novel method to expand large numbers of CD56+ natural killer cells from a minute fraction of selectively accessed cryopreserved cord blood for immunotherapy after transplantation. Cytotherapy, 2015, 17, 1582-1593.	0.3	28
36	Iron, Inflammation, and Early Death in Adults With Sickle Cell Disease. Circulation Research, 2015, 116, 298-306.	2.0	71

Xin Tian

#	Article	IF	CITATIONS
37	Airway Ciliary Dysfunction and Sinopulmonary Symptoms in Patients with Congenital Heart Disease. Annals of the American Thoracic Society, 2014, 11, 1426-1432.	1.5	38
38	Persistence of recipient human leucocyte antigen (<scp>HLA</scp>) antibodies and production of donor <scp>HLA</scp> antibodies following reduced intensity allogeneic haematopoietic stem cell transplantation. British Journal of Haematology, 2014, 166, 425-434.	1.2	26
39	Estimation of rank-tracking probabilities using nonparametric mixed-effects models for longitudinal data. Statistics and Its Interface, 2014, 7, 87-99.	0.2	5
40	Nonparametric Estimation of Conditional Distributions and Rank-Tracking Probabilities With Time-Varying Transformation Models in Longitudinal Studies. Journal of the American Statistical Association, 2013, 108, 971-982.	1.8	27
41	Nonparametric Estimation of Conditional Distribution Functions and Rank-Tracking Probabilities With Longitudinal Data. Journal of Statistical Theory and Practice, 2013, 7, 259-284.	0.3	8
42	Rapid donor Tâ€cell engraftment increases the risk of chronic graftâ€versusâ€host disease following salvage allogeneic peripheral blood hematopoietic cell transplantation for bone marrow failure syndromes. American Journal of Hematology, 2013, 88, 874-882.	2.0	5
43	High Prevalence of Respiratory Ciliary Dysfunction in Congenital Heart Disease Patients With Heterotaxy. Circulation, 2012, 125, 2232-2242.	1.6	158